GENERAL4 Sept 2026
Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug
India's drug regulator, the CDSCO, has allowed Roche to skip Phase 3 trials for a higher 920 mg dose of its multiple sclerosis drug, Ocrelizumab. The expert panel gave the waiver on condition that Roche runs a Phase 4 trial among Indian patients for the proposed indications. This could speed up local treatment access while still tracking safety.
Key Statutory Highlights
- The CDSCO expert panel granted a waiver for the 920 mg dose of Ocrelizumab.
- The waiver lets Roche skip the Phase 3 clinical trial for this higher dose.
- Roche must conduct a Phase 4 clinical trial in Indian patients for the proposed indications.
Actionable Advice for Taxpayers / Founders:No immediate action is needed for taxpayers. If you or someone you know uses this medicine, keep an eye on Roche India announcements and talk to your doctor before making any treatment changes.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: